11 results on '"Horn, Thomas"'
Search Results
2. Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study
- Author
-
Autenrieth, Michael E., Seidl, Christof, Bruchertseifer, Frank, Horn, Thomas, Kurtz, Florian, Feuerecker, Benedikt, D’Alessandria, Calogero, Pfob, Christian, Nekolla, Stephan, Apostolidis, Christos, Mirzadeh, Saed, Gschwend, Jürgen E., Schwaiger, Markus, Scheidhauer, Klemens, and Morgenstern, Alfred
- Published
- 2018
- Full Text
- View/download PDF
3. Prognostic value of computed tomography before radical cystectomy in patients with invasive bladder cancer: imaging predicts survival
- Author
-
Schmid, Sebastian Christoph, Zahel, Tina, Haller, Bernhard, Horn, Thomas, Metzger, Ilja, Holzapfel, Konstantin, Seitz, Anna K., Gschwend, Jürgen Erich, Retz, Margitta, and Maurer, Tobias
- Published
- 2016
- Full Text
- View/download PDF
4. Clinical prognosticators of survival in patients with urothelial carcinoma of the bladder and lymph node metastases after cystectomy with curative intent
- Author
-
Horn, Thomas, Schmid, Sebastian C., Seitz, Anna K., Grab, Jessica, Wolf, Petra, Haller, Bernhard, Retz, Margitta, Maurer, Tobias, Autenrieth, Michael, Kübler, Hubert R., and Gschwend, Jürgen E.
- Published
- 2015
- Full Text
- View/download PDF
5. Positron‐emission tomography imaging in urological oncology: Current aspects and developments.
- Author
-
Rauscher, Isabel, Eiber, Matthias, Weber, Wolfgang A, Gschwend, Jürgen E, Horn, Thomas, and Maurer, Tobias
- Subjects
PROSTATE cancer ,CANCER treatment ,ONCOLOGY ,POSITRON emission tomography ,CANCER chemotherapy - Abstract
Positron‐emission tomography/computed tomography combining both functional and morphological information has emerged as a powerful tool in oncological imaging within the past decades. The most commonly used radiotracer in oncology visualizing metabolic information is 2‐[18F]fluoro‐2‐deoxy‐d‐glucose. However, the use of 2‐[18F]fluoro‐2‐deoxy‐d‐glucose in urological oncology is challenging, as it is limited by physiological excretion through the urinary system. Therefore, it is only useful when applied to specific indications in selected patients with urological malignancy; for example, for detection of residual disease in the post‐chemotherapy management of patients with seminoma. Despite initial promising results in bladder cancer, no relevant additional diagnostic value with positron‐emission tomography using 2‐[18F]fluoro‐2‐deoxy‐d‐glucose or choline‐based tracers could be obtained, and should therefore be used with caution or only within clinical trials. In prostate cancer, however, a paradigm shift in imaging can be observed after development of new tracers that target the prostate‐specific membrane antigen. Biochemical recurrent prostate cancer has become a clinically widely accepted indication for prostate‐specific membrane antigen ligand positron‐emission tomography/computed tomography, with several studies showing superior detection efficacy compared with conventional imaging. For primary high‐risk prostate cancer, growing evidence suggests well‐improved staging. The present review aimed to provide an overview of the current status of positron‐emission tomography imaging in cancer of the urogenital system including the latest advances in 68Ga‐labeled and 18F‐labeled positron‐emission tomography agents targeting the prostate‐specific membrane antigen for positron‐emission tomography imaging of prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. Evaluation of Computed Tomography for Lymph Node Staging in Bladder Cancer Prior to Radical Cystectomy.
- Author
-
Horn, Thomas, Zahel, Tina, adt, Nathanja, Schmid, Sebastian C., Heck, Matthias M., Thalgott, Mark K., Hatzichristodoulou, Georgios, Haller, Bernhard, autenrieth, Michael, Kübler, Hubert R., Gschwend, Jürgen E., Holzapfel, Konstantin, and Maurer, Tobias
- Subjects
- *
BLADDER cancer treatment , *LYMPH node surgery , *COMPUTED tomography , *CYSTECTOMY , *METASTASIS - Abstract
Objectives: To retrospectively evaluate the value of CT for lymph node (LN) staging in bladder cancer. Methods: Two uroradiologists reviewed CT scans of 231 patients who underwent radical cystectomy and pelvic lymphadenectomy according to a predefined 12-field template. A 5-step model was used to grade the radiological likelihood of a LN to represent malignant spread based on size, configuration and structure as well as regional clustering. Statistical analyses were performed both on patient- and field-based levels. Results: LN metastases were found in 59 of 231 patients (25.5%). On a patient-based level, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy were 52.6, 93.6, 73.2, 85.6 and 83.4%, respectively. Using the field-based approach, a total of 1,649 anatomical fields were evaluable, of which 114 fields showed malignancy (6.9%). On a field basis, sensitivity, specificity, PPV, NPV and accuracy were 30.2, 98, 51.5, 94.5 and 93.3%, respectively. Concerning local staging (pT category), the overall accuracy was 78%; overstaging occurred in 6% and understaging in 16%. Conclusions: In line with prior studies, the sensitivity of CT imaging for the detection of LN metastases was low, while high values for specificity were achieved. This was further underlined by analyzing standardized anatomical fields. Concerning local staging, postoperative changes after TURB-T rarely led to overstaging. © 2015 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
7. Human papilloma virus is not detectable in samples of urothelial bladder cancer in a central European population: a prospective translational study.
- Author
-
Schmid, Sebastian C., Thümer, Leonore, Schuster, Tibor, Horn, Thomas, Kurtz, Florian, Slotta-Huspenina, Julia, Seebach, Judith, Straub, Michael, Maurer, Tobias, Autenrieth, Michael, Kübler, Hubert, Retz, Margitta, Protzer, Ulrike, Gschwend, Jürgen E., and Hoffmann, Dieter
- Subjects
PAPILLOMAVIRUSES ,BLADDER tumors ,ROLE playing ,EXPERIMENTAL design ,VERTEBRATES ,TRANSURETHRAL prostatectomy ,CONFIDENCE intervals ,CENTRAL Europeans ,ACQUISITION of data ,VIRUS diseases ,PAPILLOMAVIRUS diseases ,CASE studies ,POLYMERASE chain reaction ,ODDS ratio ,SENSITIVITY & specificity (Statistics) ,STATISTICAL sampling ,LONGITUDINAL method - Abstract
Background: Previous investigations on the association of human papillomavirus (HPV) and human bladder cancer have led to conflicting results. The aim of this study was to determine if low and high risk HPV play a role in the etiology of superficial low grade and invasive high grade urothelial carcinoma of the bladder. Methods: We prospectively collected tumor samples of urothelial carcinoma of the bladder from 109 patients treated with transurethral resection or cystectomy, with bladder tissue from transurethral resection of the prostate serving as control. Unfixed, frozen tumor samples were analyzed for the presence of 14 high risk HPV types using real time PCR. Additionally, all specimens were tested for 35 low risk HPV types with a conventional PCR using degenerate primers located in the L1 region. Six frozen samples of cervical carcinoma served as positive controls. Results: We included 109 cases of bladder cancer with 41 superficial (pTa low grade) tumors, 56 invasive (pT1-T4) high grade tumors and 12 others (pTa high grade + pTis). We have not detected HPV-DNA in any sample (95 % Confidence Interval [CI] 0-3.3 %), superficial tumors (95 % CI 0-6.4 %) or in invasive tumors (95 % CI 0-8.6 %) with correct positive controls. Conclusions: Using a broad, sensitive assay with prospectively collected specimens of a Central European population we could not detect HPV-DNA in any of the cases. Our results suggest that it is unlikely that HPV infections play a major role in the development of urothelial bladder cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. Prognostic Value of C-Choline PET/CT and CT for Predicting Survival of Bladder Cancer Patients Treated with Radical Cystectomy.
- Author
-
Maurer, Tobias, Horn, Thomas, Souvatzoglou, Michael, Eiber, Matthias, Beer, ambros J., Heck, Matthias M., Haller, Bernhard, Gschwend, Jürgen E., Schwaiger, Markus, Treiber, Uwe, and Krause, Bernd J.
- Subjects
- *
POSITRON emission tomography , *COMPUTED tomography , *CHOLINE , *BLADDER cancer treatment , *CYSTECTOMY , *PREOPERATIVE care - Abstract
Background: In patients with bladder cancer (BCa) preoperative staging with 11C-choline positron emission tomography-computed tomography (PET/CT) could be used to derive prognostic information and hence stratify patients preoperatively with respect to disease management. Methods: From June 2004 to May 2007, 44 patients with localized BCa were staged with 11C-choline PET/CT before radical cystectomy. The results of imaging were correlated to overall survival (OS) and cumulative incidence of cancer-specific death (CSD). Results: There was no statistically significant difference in OS and CSD between the patient groups when stratified for organ-confined versus non-organ-confined disease or lymph node involvement defined by either 11C-choline PET/CT (OS: p = 0.262, hazard ratio [HR] = 1.60; p = 0.527, HR = 0.76; CSD: p = 0.144, HR = 2.25; p = 0.976, HR = 0.98) or CT (OS: p = 0.518, HR = 1.34; p = 0.228, HR = 1.67; CSD: p = 0.323, HR = 1.90; p = 0.136, HR = 2.38). The limitation of this study is the small number of included patients. Conclusion: In our prospective trial neither CT nor 11C-choline PET/CT were able to sufficiently predict OS or CSD in BCa patients treated with radical cystectomy albeit trends and moderately increased HRs could be demonstrated without significant differences between CT or 11C-choline PET/CT. However, these trends might prove statistically significant in bigger patient cohorts. Therefore initial transsectional imaging might be of clinical relevance in respect to prognosis and could play a role in the counseling of BCa patients. © 2014 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. Microsatellite analysis of urine sediment versus urine cytology for diagnosing transitional cell tumors of the urinary bladder.
- Author
-
Fornari, Delfina, Steven, Kenneth, Hansen, Alastair B., Vibits, Henrik, Jepsen, Jan V., Poulsen, Asger L., Schwartz, Marianne, and Horn, Thomas
- Subjects
MICROSATELLITE repeats ,URINALYSIS ,CYTOLOGY ,BLADDER tumors ,DIAGNOSIS - Abstract
Fornari D, Steven K, Hansen AB, Vibits H, Jepsen JV, Poulsen AL, Schwartz M, Horn T. Microsatellite analysis of urine sediment versus urine cytology for diagnosing transitional cell tumors of the urinary bladder. APMIS 2004;112:148–52. The aim was to evaluate microsatellite analysis of urine sediment (MAUS) as an alternative method to urine cytology for routine diagnosis of patients with transitional cell tumors (TCT) of the urinary bladder. Urine cytology has the advantage of being non-invasive, fast and cheap, but is of limited value because of its low sensitivity. MAUS has previously been found to be a successful alternative method. However, the experimental set-up of such investigations implied exclusion of samples with unfavorable characteristics and use of a large number of markers. In the present study, MAUS was tested on all samples routinely available and a small panel of markers was selected. The urine sediments of 66 TCT patients and 24 controls were analyzed by MAUS with 16 fluorescent markers and by urine cytology. All samples were analyzed, including the ones of later micturition, with gross hematuria, leukocyturia or absence of visible sediment. In patients with tumors of low grade (grades I–II), MAUS was significantly more sensitive than urine cytology. The two methods were of equivalent diagnostic power in high-grade (grades III–IV), high-stage (pT1-pT4) tumors. A panel of the six most informative markers for MAUS was selected. Although MAUS has an advantage over routine cytology in low-grade, low-stage tumors, an overall sensitivity of 45% is not sufficient for routine clinical use. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
10. STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy.
- Author
-
Hindupur, Sruthi V., Schmid, Sebastian C., Koch, Jana Annika, Youssef, Ahmed, Baur, Eva-Maria, Wang, Dongbiao, Horn, Thomas, Slotta-Huspenina, Julia, Gschwend, Juergen E., Holm, Per Sonne, and Nawroth, Roman
- Subjects
BLADDER cancer ,JAK-STAT pathway ,ADENOVIRUSES ,CHORIOALLANTOIS ,CELL cycle ,CELL division - Abstract
The JAK-STAT signalling pathway regulates cellular processes like cell division, cell death and immune regulation. Dysregulation has been identified in solid tumours and STAT3 activation is a marker for poor outcome. The aim of this study was to explore potential therapeutic strategies by targeting this pathway in bladder cancer (BC). High STAT3 expression was detected in 51.3% from 149 patient specimens with invasive bladder cancer by immunohistochemistry. Protein expression of JAK, STAT and downstream targets were confirmed in 10 cell lines. Effects of the JAK inhibitors Ruxolitinib and BSK-805, and STAT3/5 inhibitors Stattic, Nifuroxazide and SH-4-54 were analysed by cell viability assays, immunoblotting, apoptosis and cell cycle progression. Treatment with STAT3/5 but not JAK1/2 inhibitors reduced survival, levels of phosphorylated STAT3 and Cyclin-D1 and increased apoptosis. Tumour xenografts, using the chicken chorioallantoic membrane (CAM) model responded to Stattic monotherapy. Combination of Stattic with Cisplatin, Docetaxel, Gemcitabine, Paclitaxel and CDK4/6 inhibitors showed additive effects. The combination of Stattic with the oncolytic adenovirus XVir-N-31 increased viral replication and cell lysis. Our results provide evidence that inhibitors against STAT3/5 are promising as novel mono- and combination therapy in bladder cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. Outcomes of palliative cystectomy in patients with locally advanced pT4 bladder cancer.
- Author
-
Maisch, Phillipp, Lunger, Lukas, Düwel, Charlotte, Schmid, Sebastian C., Horn, Thomas, Gschwend, Jürgen E., Sauter, Andreas, and Heck, Matthias M.
- Subjects
- *
BLADDER cancer , *LOG-rank test , *OVERALL survival , *CYSTECTOMY , *URINARY diversion , *SURGICAL complications , *RETROSPECTIVE studies , *TREATMENT effectiveness , *TUMOR classification , *PALLIATIVE treatment ,BLADDER tumors - Abstract
Background: Radical cystectomy (Cx) is the standard of care for muscle-invasive bladder cancer (BCa). In locally advanced pT4 BCa the oncologic outcome is inexplicit but Cx may be necessary for palliation.Objectives: The aim of this retrospective study was to evaluate the outcomes of Cx performed in patients with locally advanced pT4 BCa and to identify patient subgroups with improved outcome.Methods: Between 2008 and 2017, we identified 76 of 905 patients who underwent Cx for pT4 BCa at a single tertiary referral center. The physical patients' status was estimated according to the American Society of Anesthesiologists (ASA) classification. For the classification of postoperative complication rates, the Clavien-Dindo grading was used. Time-to-event variables with log-rank statistics were calculated with the use of the Kaplan-Meier method.Results: Median age was 74 years (range 42-90). Preoperatively, the physical status was estimated poor in 40 (52%) patients (ASA-score of ≥3). Overall, 19 (25%) patients had pT4b BCa, 41 (54%) patients were lymph node positive (c/pN+) and 14 (18%) patients had distant metastases (c/pM+). Within 30 and 90 days after surgery, 21% and 30% of the patients, respectively, developed severe complications (Clavien-Dindo grade ≥3). Overall, 30- and 90-day mortality rates were 9% and 11%, respectively. Moreover, 86% and 75% of patients who died within 30 and 90 days after surgery, respectively, had an ASA-score ≥3. At a median postoperative follow-up of 8 months (range 0-85), 53 (70%) patients have died. During the follow-up period, 46% of the patients died due to progressive disease, 16% died of a noncancer-specific cause, and for 8% of the patients, the reason remains unknown. Median overall survival (OS) and cancer-specific survival were 13.0 and 16.0 months, respectively. In subgroup analyses ASA-score ≥3 and hemoglobin <11.7 g/dl was significantly associated with poor OS. No statistically significant differences were detected between subgroups.Conclusion: Cx performed in patients with locally advanced pT4 BCa is associated with an increased mortality rate within 90 days postoperatively. Our study revealed that the ASA-score is a relevant and easily available tool to rate the patient´s condition and estimate postoperative outcome. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.